Anxiolytic properties of cyamemazine: The role of serotonin receptors;Activité anxiolytique de la cyamémazine: Rôle des récepteurs sérotoninergiques

Information Psychiatrique

Volumn 83, Issue 7, 2007, Pages 595-601

  Nuss, Philippe ^a   Llorca, Pierre Michel ^b   Lançon, Christophe ^a   Garay, Ricardo ^c   Hodé, Yann ^d   Hameg, Ahcène ^e   Baylé, Franck ^f  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c SANOFI   (France)

^d FORENAP   (France)

^e HÔPITAL SAINTE MARGUERITE   (France)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Antipsychotic drug; Cyamemazine; Neuroleptic; Receptor; Serotonin

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; CYAMEMAZINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RACLOPRIDE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN RECEPTOR; SULPIRIDE;

BINDING AFFINITY; CELL MEMBRANE; DEPRESSION; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; FRANCE; GENETIC TRANSFECTION; HUMAN; HYPOTHERMIA; ISOLATED ORGAN; MOLECULAR IMAGING; MONOAMINERGIC SYSTEM; NEUROPHARMACOLOGY; NONHUMAN; PRESCRIPTION; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; TRANQUILIZING ACTIVITY;

EID: 35348938551     PISSN: 00200204     EISSN: None     Source Type: Journal    
DOI: 10.1684/ipe.2007.0219     Document Type: Review

References (37)

1. DELAY J, DENIKER P, HARL JM. Traitement des états d'excitation et d'agitation par une méthode médicamenteuse dérivée de l'hivernothérapie. Ann Med Psych 1952 ; 110 : 267-73.
2. LAMBERT PA, REVOL L. Classification of neuroleptics. Compr Psychiatry 1969 ; 10 : 50-8.
3. POIRIER-LITTRE MF, LONGEVIALLE-HENIN R, JOLY H, GINESTET D, DENIKER P. Attempt at classification and orientation of prescriptions using an index of psychotropic drugs in computers. Encephale 1975 ; 1 : 113-20.
4. CARLSSON A, LINDQVIST M. Effects of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963 ; 20 : 140-4.
5. STRANGE PG. Antipsychotic drugs : importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001 ; 53 : 119-33.
6. SEEMANP, CHAU-WONG M, TEDESCO J, WONG K. Brain receptors for antipsychotic drugs and dopamine : direct binding assays. Proc Natl Acad Sci USA 1975 ; 72 : 4376-80.
7. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science ;192 :481-3.
8. MELTZER HY. Action of atypical antipsychotics. Am J Psychiatry 2002 ; 159: 153-5.
9. GEDDES J, FREEMANTLE N, HARRISON P, BEBBINGTON P. Atypical antipsychotics in the treatment of schizophrenia : systematic overview and meta-regression analysis. BMJ 2000 ; 321 : 1371-6.
10. GURY C, BERCHOT F, FABRE C, SURUGUE J, WELCOMME N. Analyse des prescriptions de neuroleptiques dans cinq centres hospitaliers spécialisés : comparaisons entre prescriptions hospitalières et prescriptions de sortie. Inf Psychiatr 2000 ; 76 : 954-63.
11. FOURRIER A, GASQUETI, ALLICAR MP, BOUHASSIRA M, LÉPINE JP, BÉGAUD B. Patterns of neuroleptic drug prescription : a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 2000 ; 49 : 80-6.
12. BRUNOT A, LACHAUX B, SONTAG H, et al. Pharmacoepidemiological study on antipsychotic drug prescription in French psychiatry : patient characteristics, antipsychotic treatment, and care management for schizophrenia. Encephale 2002 ; 28 : 129-38.
13. RADAT F. Cyamémazine : traitement symptomatique des dimensions anxieuses, impulsives et agressives. Inf Psychiatr 1995 ; 10 : 967-8.
14. ROPERT R. L'emploi de la cyamémazine à faibles doses dans le traitement des affectations non psychotiques. Inf Psychiatr 1975 ; 51 : 87-94.
15. LAMBERT PA. Classification des neuroleptiques. Actual Ther Psychiat 1963 ; 1 : 61-78.
16. GARAY RP, D'ALCHE-BIREE F. Cyamémazine : profil neuroleptique ou anxiolytique? Inf Psychiatr 1995 ; 71 : 969-71.
17. 2c-antagonist properties of cyamemazine : significance for its clinical anxiolytic activity. Psychopharmacology (Berl) 2000 ; 147 : 412-7.
18. 2A antagonist properties of cyamemazine in rat and guinea pig smooth muscle. Eur J Pharmacol 2002 ; 454 : 235-9.
19. PEINADO J, HAMEG A, GARAY RP, BAYLE F, NUSS P, DIB M. Reduction of extracellular dopamine and metabolite contents by low doses of acute cyamemazine in rat striatum. Naunyn-Schmiedberg's Arch Pharmacol 2003 ; 367 : 134-9.
20. PEHEK EA, YAMAMOTO BK. Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate putamen. J Neurochem 1994 ; 63 : 2118-24.
21. HERNANDEZ L, HOEBEL BG. Chronic clozapine selectively decreases prefrontal cortex dopamine as shown by simultaneous cortical, accumbens and striatal dialysis in freely moving rats. Pharmacol Biochem Behav 1995 ; 52 : 581-9.
22. HAMEG A, BAYLE F, NUSS P, DUPUIS P, GARAY RP, DIB M. Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. Serotonin receptor subtypes. Biochem Pharmacol 2003 ; 65 : 435-40.
23. HODE Y, REIMOLD M, DEMAZIERES A, et al. A positron émission tomography (PET) study of cerebral dopamine (D (2) and Serotonine 5-HT (2A) receptor occupancy in patients treated with cyamemazine (Tercian). Psychopharmacology (Berlin) 2005 ; 180 : 377-84.
24. BOURIN M, DHONNCHADHA BAN, COLOMBEL MC, DIB M, HASCOET M. Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Behav Brain Res 2001 ; 124 : 87-95.
25. e CINP Congress. Paris.
26. SCHWANINGER M, WEISBROD M, SCWAB S, SCHRODER M, HACKE W. Hypothermia induced by atypical neuroleptics. Clin Neuropharmacol 1998 ; 21 : 344-6.
27. CHARNEY DS, WOODS SW, GOODMAN WK, HENINGER GR. Serotonin function in anxiety. II. Effects of the serotonin antagonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987 ; 92 : 14-24.
28. DUNCAN GE, ZORN S, LIEBERMAN JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry 1995 ; 4 : 418-28.
29. BLIN O, AZORIN JM, BOOURHOURS P. Antipsychotic and anxiolytic properties of risperidone, haloperidol and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996 ; 16 : 38-44.
30. KAPLAN M. Atypical antipsychotics for treatment of mixed depression and anxiety. J Clin Psychiatry 2000 ; 61 : 388-9.
31. BARNETTS D, KRAMER ML, CASAT CD, CONNOR KM, DAVIDSON JR. Efficacy of olanzapine in social anxiety disorder : a pilot study. J Psychopharmacol 2002 ; 16 : 365-8.
32. SAJATOVIC M. Treatment for mood and anxiety disorders : quetiapine and aripiprazole. Curr Psychiatry Rep 2003 ; 5 : 320-6.
33. GRIEBEL G, PERRAULT G, SANGER DJ. A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 1997 ; 36 : 793-802.
34. BROMIDGE SM, DABBS S, DAVIES DT, et al. Biarylcarbamoylindolines are novel and selective 5-HT (2C) receptor inverse agonists : identification of 5-methyl-1-2- [(2-methyl-3-pyridyl) oxy]-5-pyridyl] carbamoyl]-6-trifluoromethyl-indoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem 2000 ; 43 : 1123-34.
35. MARTIN JR, BALLARD TM, HIGGINS GA. Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav 2002 ; 71 : 615-25.
36. CEULEMANS DL, HOPPENBROUWERS ML, GELDERS YG, REYNTJENS AJ. The influence of ritanserin, a serotonin antagonist, in anxiety disorders : a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 1985 ; 18 : 303-5.
37. 3 receptor antagonists in development as anxiolytics. Exp Opin Invest Drugs 1995 ; 4 : 333-42.